Therapeutic Plasma Exchange Market Size, Share, Growth, and Industry Analysis, By Type (Neurological,Autoimmune Disorder), By Application (Guillain Barre Syndrome,Multiple Sclerosis,Myasthenia Gravis,Thrombotic Thrombocytopenic Purpura,Glomerulonephritis), Regional Insights and Forecast to 2035

Therapeutic Plasma Exchange Market Overview

The global Therapeutic Plasma Exchange Market size is projected to grow from USD 610.02 million in 2026 to USD 668.64 million in 2027, reaching USD 1393.1 million by 2035, expanding at a CAGR of 9.61% during the forecast period.

The therapeutic plasma exchange market is growing rapidly with more than 2.5 million therapeutic plasma exchange (TPE) procedures performed annually worldwide by 2024, up from 1.8 million in 2020. Around 43% of global plasma exchange treatments are conducted for neurological disorders, while autoimmune conditions account for 38% of procedures. There are currently more than 3,200 hospitals and specialty clinics globally providing TPE services, with North America contributing nearly 41% of overall treatment volume. In 2025, more than 67% of plasma exchange machines are expected to be installed in tertiary care hospitals, driven by rising demand in neurology and nephrology.

In the USA, more than 950,000 therapeutic plasma exchange procedures were performed in 2024, representing 38% of the global total. Approximately 47% of these procedures were conducted for neurological conditions such as Guillain-Barré Syndrome and Myasthenia Gravis. Over 1,200 hospitals and specialty clinics in the country are equipped with TPE systems, with 68% of them concentrated in urban centers. Plasma exchange demand in the U.S. healthcare system rose by 27% between 2020 and 2024 due to increasing autoimmune and renal disorder prevalence. The U.S. market is led by companies like Baxter and Terumo BCT, which together supply 58% of installed plasma exchange equipment.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 63% of procedures are driven by neurological disorders, while 48% of demand stems from autoimmune diseases.
• Major Market Restraint: 39% of patients in low-income regions face affordability issues, and 42% of smaller hospitals lack TPE equipment.
• Emerging Trends: 52% of new installations include AI-driven monitoring, and 37% integrate automated filtration systems.
• Regional Leadership: North America contributes 41% of global volume, Europe 29%, Asia-Pacific 24%, and Middle East & Africa 6%.
• Competitive Landscape: Top five companies control 62% of the global supply, with two leaders holding more than 37% combined.
• Market Segmentation: Neurological indications account for 43%, autoimmune disorders 38%, and renal-related conditions 19% of total treatments.
• Recent Development: 46% of devices launched since 2023 include portable designs, and 33% feature single-use disposable kits.

Therapeutic Plasma Exchange Market Latest Trends

Therapeutic plasma exchange market trends highlight the integration of advanced filtration and AI-powered monitoring systems. In 2024, over 52% of new machines installed were equipped with AI-enabled monitoring modules that tracked plasma removal accuracy and patient vitals in real time. Disposable kit usage grew by 39% since 2020, with over 4.2 million disposable plasma exchange kits used in 2024 alone. Portable plasma exchange systems gained prominence, with 28% of new hospital installations adopting compact models suitable for bedside treatments. Hospitals reported a 31% reduction in average plasma exchange session time, from 120 minutes to 82 minutes, due to automation.

Therapeutic Plasma Exchange Market Dynamics

DRIVER

"Rising prevalence of neurological and autoimmune disorders"

The major driver of the therapeutic plasma exchange market is the rising prevalence of neurological conditions and autoimmune disorders. Globally, 43% of TPE procedures are conducted for neurological diseases, while 38% are for autoimmune diseases. In 2024, Guillain-Barré Syndrome accounted for more than 160,000 plasma exchange treatments, and Myasthenia Gravis for over 120,000. Hospitals in Europe reported a 27% increase in plasma exchange usage for multiple sclerosis since 2020, while North America recorded 21% growth for Myasthenia Gravis-related treatments. This rising disease burden is fueling demand for advanced TPE machines and disposable kits worldwide.

RESTRAINT

"High equipment and procedure costs"

One of the major restraints is the high cost of TPE procedures and equipment. More than 42% of small and mid-sized hospitals report lacking access to plasma exchange systems due to upfront installation costs. A single TPE machine costs 25–30% more than conventional dialysis systems, making adoption challenging in low-resource healthcare settings. In Africa, only 15% of tertiary care hospitals are equipped with TPE units, restricting patient access. Patient affordability remains a challenge, with 39% of candidates in low-income countries unable to undergo recommended treatments.

OPPORTUNITY

"Expansion in portable and disposable plasma exchange systems"

A key opportunity is the expansion of portable plasma exchange systems and disposable kits. In 2024, 28% of new installations were portable models, allowing greater hospital and home-care adoption. Disposable kit demand rose by 39%, with over 4.2 million kits sold globally. These innovations reduce procedure time, enhance infection control, and make TPE more accessible to smaller healthcare centers. Asia-Pacific presents strong opportunities, with 120 new hospitals expected to adopt TPE by 2026 due to the availability of lower-cost portable units.

CHALLENGE

"Shortage of trained professionals and infrastructure gaps"

A major challenge is the shortage of trained professionals and infrastructure. More than 45% of hospitals in emerging economies lack adequate staff trained in therapeutic plasma exchange. In India, only 220 specialists are certified to perform advanced TPE, while demand exceeds 450 annually. In Africa, 70% of hospitals capable of offering TPE report delays due to lack of skilled staff. Infrastructure gaps, such as insufficient ICU beds and limited cold chain facilities for plasma storage, also hinder widespread adoption.

Therapeutic Plasma Exchange Market Segmentation

The therapeutic plasma exchange market is segmented by type and application, highlighting the dominance of neurological and autoimmune treatments, as well as diverse clinical uses across multiple disease areas.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Neurological: Neurological disorders account for 43% of global plasma exchange demand, with more than 1.1 million procedures performed in 2024. Guillain-Barré Syndrome, multiple sclerosis, and Myasthenia Gravis drive this category. In the USA, 47% of neurological TPE treatments target GBS patients. Hospitals in Europe recorded a 29% increase in neurology-related TPE procedures between 2020 and 2024.

Autoimmune Disorder: Autoimmune disorders contribute 38% of total TPE treatments globally, with 950,000 procedures performed in 2024. Systemic lupus erythematosus and rheumatoid arthritis are major contributors, with 33% of autoimmune patients undergoing TPE therapy annually. Asia-Pacific recorded a 25% rise in autoimmune TPE procedures in 2024, particularly in China and India.

BY APPLICATION

Guillain-Barré Syndrome: Over 160,000 TPE procedures were performed globally in 2024 for GBS, representing 14% of total applications. In North America, 60,000 patients were treated with plasma exchange for GBS.

Multiple Sclerosis: TPE procedures for multiple sclerosis exceeded 140,000 globally in 2024, accounting for 12% of all applications. Europe accounted for 41% of this volume, with Germany and France leading adoption.

Myasthenia Gravis: More than 120,000 procedures were conducted in 2024 for Myasthenia Gravis, representing 10% of global applications. The USA performed 45,000 of these treatments.

Thrombotic Thrombocytopenic Purpura (TTP): TTP accounted for 85,000 TPE treatments worldwide in 2024, with 32% performed in North America. Europe contributed 27% of this segment.

Glomerulonephritis: More than 95,000 plasma exchange treatments were carried out in 2024 for glomerulonephritis patients, representing 8% of total applications. Asia-Pacific accounted for 38% of this volume, particularly in India and China.

Therapeutic Plasma Exchange Market Regional Outlook

North America leads with 41% share, performing over 950,000 procedures annually, with the U.S. accounting for 770,000 cases and Canada contributing 115,000. Europe holds 29% share, led by Germany’s 195,000 treatments, France’s 130,000, and the UK’s 109,000. Asia-Pacific captures 24% share with China conducting 234,000 procedures, India 156,000, and Japan 108,000, while Middle East & Africa represent 6%, led by UAE’s 50,000 and Saudi Arabia’s 43,000 annual plasma exchange cases.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounts for 41% of the therapeutic plasma exchange market, performing more than 950,000 annual procedures in 2024. The United States dominates with 81% of the regional volume, treating approximately 770,000 patients annually across neurology and autoimmune cases. Canada contributes 12% of regional demand with over 115,000 procedures, while Mexico represents 7% with around 65,000 treatments. Hospitals in the region reported a 27% increase in plasma exchange usage between 2020 and 2024, particularly for Guillain-Barré Syndrome and Myasthenia Gravis. More than 1,200 U.S. hospitals are equipped with plasma exchange machines, ensuring advanced adoption across tertiary centers.

EUROPE

Europe represents 29% of global share, with more than 725,000 plasma exchange procedures completed in 2024. Germany leads with 27% of Europe’s volume, performing 195,000 procedures annually across 450 specialized centers. France contributes 18%, accounting for over 130,000 plasma exchange cases, while the United Kingdom represents 15% with 109,000 treatments. Spain and Italy collectively hold 21% of the European total, with around 152,000 procedures combined. Demand is primarily driven by neurological cases such as multiple sclerosis, which increased by 29% since 2020. Cross-border healthcare initiatives further enhance patient access to TPE across EU member states.

ASIA-PACIFIC

Asia-Pacific holds 24% of the therapeutic plasma exchange market, performing more than 600,000 annual procedures. China dominates with 39% of the regional share, completing 234,000 TPE treatments in 2024 across 600 hospitals. India follows with 26% of regional demand, conducting 156,000 procedures annually, with strong adoption in government hospitals. Japan contributes 18% share, with 108,000 treatments annually focused on renal and neurological applications. Australia and South Korea together represent 12% share, managing 72,000 cases combined. The region reported a 25% rise in autoimmune disorder-related TPE demand between 2020 and 2024, driven by rising prevalence and expanding access to portable devices.

MIDDLE EAST & AFRICA

Middle East & Africa account for 6% of the market, performing approximately 150,000 plasma exchange procedures in 2024. The UAE leads with 33% of the regional share, managing 50,000 treatments annually, driven by private hospital adoption. Saudi Arabia follows with 29%, recording 43,000 procedures annually through Vision 2030-driven healthcare expansion. South Africa holds 18% of regional share, completing 27,000 procedures across 65 hospitals. Nigeria and Egypt together contribute 12% with more than 18,000 cases annually. Infrastructure limitations remain, but plasma exchange adoption increased by 36% since 2020, reflecting strong demand in government and private healthcare facilities.

List of Top Therapeutic Plasma Exchange Companies

• Baxter International Inc.
• Asahi Kasei Medical Co.
• Terumo BCT, Inc.
• Kawasumi Laboratories Inc.
• Haemonetics Corporation
• B. Braun Melsungen AG
• HemaCare Corporation
• Fresenius Medical

Top 2 Companies with Highest Market Share:

• Baxter International Inc. controls 21% of global supply, with over 1,200 plasma exchange systems installed worldwide.
• Fresenius Medical holds 16% share, providing more than 950,000 disposable kits annually across 70 countries.

Investment Analysis and Opportunities

Investments in therapeutic plasma exchange are accelerating, with over 400 new TPE centers established globally between 2020 and 2024. More than USD 1.5 billion was allocated to expanding TPE equipment manufacturing facilities in this period. Asia-Pacific hospitals invested in 120 new installations in 2024, representing a 25% increase from 2021. Private equity firms invested in three major TPE equipment startups in 2023–2025, targeting affordable portable units. Opportunities lie in expanding TPE availability to emerging markets, as only 15% of hospitals in Africa and 32% in Southeast Asia currently offer plasma exchange procedures.

New Product Development

Product innovation is reshaping the TPE market. Between 2023–2025, 46% of new devices launched featured portable designs, enabling bedside use. Baxter launched a plasma exchange unit reducing treatment duration by 25%, lowering sessions from 120 minutes to 90 minutes. Fresenius developed disposable kits with a 30% improvement in plasma separation efficiency. Terumo BCT introduced cloud-enabled TPE machines connected to EMR systems, adopted in over 250 hospitals by 2024. Asahi Kasei Medical released dual-mode devices capable of both plasma exchange and immunoadsorption, improving treatment flexibility.

Five Recent Developments

• Baxter introduced portable plasma exchange machines used in 220 hospitals worldwide (2023).
• Fresenius launched disposable plasma kits with 30% improved efficiency, adopted in 18 countries (2024).
• Terumo BCT integrated cloud monitoring features into 300 new machines (2024).
• Asahi Kasei Medical expanded TPE device production by 40% in Japan (2023).
• Haemonetics rolled out AI-driven monitoring systems in 180 hospitals (2025).

Report Coverage

This report covers the therapeutic plasma exchange market comprehensively across type, application, and region. It evaluates over 2.5 million annual TPE procedures, segmented into neurological, autoimmune, and renal indications. The analysis covers applications such as Guillain-Barré Syndrome, multiple sclerosis, Myasthenia Gravis, TTP, and glomerulonephritis, with detailed adoption figures. Regional coverage highlights North America’s 41% share, Europe’s 29%, Asia-Pacific’s 24%, and MEA’s 6%. Competitive analysis includes eight leading companies, with Baxter and Fresenius leading global market presence. The report highlights investments exceeding USD 1.5 billion, product innovations such as AI-driven monitoring, and five major developments between 2023–2025.

Therapeutic Plasma Exchange Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 610.02 Million in 2026
Market Size Value By	USD 1393.1 Million by 2035
Growth Rate	CAGR of 9.61% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Neurological Autoimmune Disorder By Application : Guillain Barre Syndrome Multiple Sclerosis Myasthenia Gravis Thrombotic Thrombocytopenic Purpura Glomerulonephritis
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample